Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05917587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jul 2028 to Dec 31, 2027
    • Study completion date: Jul 2029 to Jun 30, 2028
    v7
  2. Re-verified, no change to tracked fieldsv6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2024 to Sep 11, 2024
    v5
  4. Start date: Jun 2024 to Aug 2024v4
  5. Start date: Feb 2024 to Jun 2024v3
  6. Start date: Aug 2023 to Feb 2024v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Anna Stanhewicz, PhD
12 trials monitored
See 1 trial at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
Trial Details
NCT Number NCT05917587
Lead Sponsor Anna Stanhewicz, PhD
Conditions
(from sponsor)		 Gestational Diabetes
Related terms Diabetes, Gestational
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov